We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
-8.87%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$2.94B
AUM Growth
-$1.55B
Cap. Flow
-$352M
Cap. Flow %
-11.97%
Top 10 Hldgs %
43.7%
Holding
135
New
15
Increased
7
Reduced
68
Closed
31

Top Buys

Rank Stock Value
1
GLUE icon
Monte Rosa Therapeutics
GLUE
+$65.1M
2
BMEA icon
Biomea Fusion
BMEA
+$56M
3
JBIO
Jade Biosciences
JBIO
+$46.4M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$46M
5
AMAM
Ambrx Biopharma Inc
AMAM
+$42.4M

Top Sells

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$76.5M
2
APLS
Apellis Pharmaceuticals
APLS
+$52.4M
3
NVAX icon
Novavax
NVAX
+$45.3M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$43.6M
5
OMER icon
Omeros
OMER
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 86.97%
2 Miscellaneous 12.9%
3 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$237M 8.05%
3,037,042
+287,042
+10% +$21.2M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$77.2B
$229M 7.79%
1,000,000
-1,000,000
-50% -$225M
AVIR icon
3
Atea Pharmaceuticals
AVIR
$417M
$138M 4.68%
6,411,355
– –
FMTX
4
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$118M 3.99%
4,721,589
+1,589
+0% +$42.7K
BBIO icon
5
BridgeBio Pharma
BBIO
$13.4B
$115M 3.9%
1,880,980
-287,929
-13% -$16.4M
DSGN icon
6
Design Therapeutics
DSGN
$788M
$106M 3.6%
5,414,850
+300,000
+6% +$7.57M
RVMD icon
7
Revolution Medicines
RVMD
$42.4B
$106M 3.6%
3,338,166
+813,166
+32% +$28.4M
OLMA icon
8
Olema Pharmaceuticals
OLMA
$850M
$86M 2.92%
3,073,485
-122,059
-4% -$3.47M
BCAB
9
DELISTED
BIOATLA INC
BCAB
$82.7M 2.81%
39,034
-4,807
-11% -$10.9M
GLUE icon
10
Monte Rosa Therapeutics
GLUE
$1.09B
$69.5M 2.36%
+3,193,973
New +$65.1M
ARKG icon
11
PUT
ARK Genomic Revolution ETF
ARKG
$2.03B
$69.4M 2.36%
+750,000
New +$63.8M
EWTX icon
12
Edgewise Therapeutics
EWTX
$4.82B
$66.5M 2.26%
3,140,914
+800,000
+34% +$21.9M
ARKK icon
13
PUT
ARK Innovation ETF
ARKK
$6.45B
$65.4M 2.22%
+500,000
New +$58.3M
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$55.1M 1.87%
2,228,667
-235,878
-10% -$5.49M
APLS
15
DELISTED
Apellis Pharmaceuticals
APLS
$53.7M 1.82%
850,000
-1,016,108
-54% -$52.4M
ALXO icon
16
ALX Oncology
ALXO
$252M
$48.6M 1.65%
889,454
+7,684
+0.9% +$460K
BMEA icon
17
Biomea Fusion
BMEA
$125M
$48.4M 1.65%
+3,170,872
New +$56M
AMAM
18
DELISTED
Ambrx Biopharma Inc
AMAM
$47M 1.6%
+2,486,386
New +$42.4M
ZYME icon
19
Zymeworks
ZYME
$1.87B
$45.9M 1.56%
1,321,936
-678,064
-34% -$21.5M
JBIO
20
Jade Biosciences
JBIO
$1.06B
$44.6M 1.52%
+58,020
New +$46.4M
RXDX
21
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$44.5M 1.51%
1,848,024
-250,000
-12% -$5.58M
TARS icon
22
Tarsus Pharmaceuticals
TARS
$3.71B
$43.9M 1.49%
1,514,269
-200,000
-12% -$6.25M
STOK icon
23
Stoke Therapeutics
STOK
$1.82B
$43M 1.46%
1,278,276
-159,531
-11% -$5.64M
RCKT icon
24
Rocket Pharmaceuticals
RCKT
$382M
$42.9M 1.46%
968,550
-400,000
-29% -$17.4M
VERV
25
DELISTED
Verve Therapeutics
VERV
$40.6M 1.38%
+709,224
New +$29.4M
1
2 3 4 5

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Cormorant Asset Management held 135 positions worth $2.94B, down 34% from $4.49B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management withdrew a net $352M in Q2 2021, closing 31 positions and reducing 68 holdings. Its most notable exit was Novavax, an estimated $45.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 77% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Cormorant Asset Management opened a new position in Monte Rosa Therapeutics worth $69.5M.

  • Cormorant Asset Management's largest Q2 2021 buy was Monte Rosa Therapeutics: 3,193,973 shares worth $69.5M.
  • Cormorant Asset Management added most to Revolution Medicines in Q2 2021, an estimated $28.4M increase.
  • Cormorant Asset Management's biggest Q2 2021 reduction was C4 Therapeutics, cutting an estimated $76.5M.
  • Cormorant Asset Management fully exited Novavax in Q2 2021, selling an estimated $45.3M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2021.
  • Cormorant Asset Management opened 15 new positions and closed 31 in Q2 2021.
  • Cormorant Asset Management's portfolio value fell 34% quarter-over-quarter to $2.94B.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.